about
Liver transplantation for alcoholic liver disease: Lessons learned and unresolved issuesMulticenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patientsIs chronic hepatitis C virus infection a risk factor for breast cancer?Comparison of serum HBsAg quantitation by four immunoassays, and relationships of HBsAg level with HBV replication and HBV genotypes.MELD Score Kinetics in Decompensated HIV+/HCV+ Patients: A Useful Prognostic Tool (ANRS HC EP 25 PRETHEVIC Cohort Study).Drug-induced acute liver failure.Cytokine Response Associated with Hepatitis C Virus Clearance in HIV Coinfected Patients Initiating Peg Interferon-α Based Therapy.Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT studyEffectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in FranceProtease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.Patient adherence issues in the treatment of hepatitis C.Addictive behaviors in liver transplant recipients: The real problem?Alcohol use and smoking after liver transplantation; complications and prevention.Direct acting antiviral agents-based regimen for HCV recurrence after combined liver-kidney transplantation: results from the ANRS CO23 CUPILT study.Sofosbuvir-based Regimens in HIV/HCV Coinfected Patients after Liver Transplantation: Results from the ANRS CO23 CUPILT Study.Follow-Up of Alcohol Consumption After Liver Transplantation: Interest of an Addiction Team?Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT).Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study.Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.[Quality of life in adult liver transplant recipients].The role of genetic factors in patients with hepatocellular carcinoma and iron overload - a prospective series of 234 patients.Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication.Patients with acute liver failure listed for superurgent liver transplantation in France: reevaluation of the Clichy-Villejuif criteria.[Non-viral fulminant hepatitis].Acute hepatitis and renal failure related to intranasal buprenorphine misuse: case report and analysis of cases reported to the French network for drug monitoring.Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.Primary sclerosing cholangitis: a new cause of distal renal tubular acidosis.Evaluation of two sirolimus assays using the ARCHITECT-i1000(®) CMIA or RxL(®) ACMIA methods in comparison with the IMx(®) MEIA method.Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis.Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients.Long-term outcomes of liver transplantation: diabetes mellitus.Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
P50
Q26780281-AE9F7A38-3558-4487-83FF-52EF8AE6BA5CQ33426112-1BA2F5AE-1E56-4435-89A1-8FFF216B8B74Q33557819-D40DF4E1-70F6-4564-B0FD-1F7D85A1439CQ33575450-ABDB3048-B232-4D47-B4DC-296641749B61Q33866483-E009F81F-17DA-4A8D-9605-F2FF21F933E3Q34041411-F6DE2E72-5ED1-46B3-9DB0-AE7479F2D3C7Q34189348-42EEE693-9DF2-4793-A6FA-AF8244FB95F9Q36009355-6CE3FC84-64E6-4604-AA54-941AE98DD630Q36021417-24B5EE18-6A19-4E9A-A3DE-77AB92451953Q36417572-CB686AD1-756A-49DB-A08A-54210AFC6BD1Q36597715-E244B27C-B79B-47EA-AD0A-11ADEA68E61CQ37250436-5E24193F-D5F0-4DE4-8AFB-8F04413F8899Q38034548-807C9EF0-775A-44F8-AA38-1F5A23A34C1DQ38153794-97609964-F5A2-4546-8AB0-BCCCC2BF097FQ38219639-15ED991E-3E7E-4644-A750-2ABB5E597C0FQ38609237-0DDEF9B0-BFCE-4779-B0B9-B175EB2B10F4Q39379830-FB947A75-79DE-4D61-84FF-E87EDEC87A14Q40051223-09199ED7-1360-42CB-9A49-BCBCD492E831Q40068076-6724C547-5F28-46D8-9517-0FB2171D53F4Q40432273-B7921379-17DE-47AF-B27D-4497D9978766Q40476119-BB39EA29-A102-4979-BBFE-D3FC2184B671Q40565478-224AAF40-A406-41F9-A18E-08CA7375E4F5Q40635393-259E1100-16D2-4D70-878A-2005793684C9Q40645429-05C345B2-AC80-48DC-B1AC-AEDE3CB83FB6Q40741790-96B8A730-1EE4-4253-92AE-961AF2CD82E8Q40868665-0B0A691E-C0D9-4B71-9565-0A3519059A56Q40893258-42D8D8C6-AE0A-4416-92F7-CE3E8ED68AE7Q41209458-BED97250-9D03-45D6-845D-24AA88336C64Q41591012-255DB8A4-F9F3-4830-8CBA-048CDCFC9E82Q41956652-E2008C6E-AE84-47B6-A7DC-F4E940BFE70BQ42172133-30D47C67-FCE6-4B8D-949F-711A90395EFDQ42254138-4DEF2B2F-C819-4740-9E8E-8D2A7CD73E25Q42272968-053B34B1-82FF-47FF-A306-4986F8C92A29Q42350633-51EC7AAF-B8F4-4D1A-9D74-60D797B6838FQ42953737-A2B2D506-9249-4D55-BBD4-0913501FCD4BQ42980542-1400177D-7EA8-4B15-9B5F-09C9582D96B8Q42987036-D14418D4-7DAA-4890-8B04-6235E98F75D9Q43056158-F727B8AF-210E-48A5-AC78-1E4DFDC482F5Q43251982-0443C6F7-70D8-4E55-BA1A-CAE91D8A5090Q43283437-F0B66C26-8910-46E8-A2AF-CBDD4B3FC6F9
P50
description
onderzoeker
@nl
name
Georges-Philippe Pageaux
@ast
Georges-Philippe Pageaux
@en
Georges-Philippe Pageaux
@es
Georges-Philippe Pageaux
@nl
Georges-Philippe Pageaux
@sl
type
label
Georges-Philippe Pageaux
@ast
Georges-Philippe Pageaux
@en
Georges-Philippe Pageaux
@es
Georges-Philippe Pageaux
@nl
Georges-Philippe Pageaux
@sl
prefLabel
Georges-Philippe Pageaux
@ast
Georges-Philippe Pageaux
@en
Georges-Philippe Pageaux
@es
Georges-Philippe Pageaux
@nl
Georges-Philippe Pageaux
@sl